Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Zhonghui Biotech-B (02627) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to CICC research, Zhonghui Biotech-B is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing duration [1] Group 2 - Zhonghui Biotech-B announced that the National Medical Products Administration of China has approved its new drug application for a trivalent influenza virus subunit vaccine for all age groups [1] - This vaccine is the first and only fully approved trivalent influenza virus subunit vaccine for the entire population in China [1] - The product represents a significant upgrade over traditional virus split vaccines, offering comprehensive protection, high purity of antigen components, and lower risk of adverse reactions [1]
中慧生物-B获纳入恒生综合指数 有望成为港股通标的